Dear Dr. Melfi:

Please refer to your supplemental new drug applications dated October 12, 2004, received October 13, 2004 (S-004), and January 28, 2005 received January 31, 2005 (S-005) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cialis® (tadalafil), 5mg, 10mg and 20mg.

We also acknowledge receipt of your amendments to S-004 dated January 24, 2005.

The “Prior Approval” supplement (S-004) provides a response to a Supplement Request Letter dated October 8, 2004 to delete the contraindication regarding the concomitant use of Cialis® and alpha-blockers and replace with a new “Alpha-Blockers” subsection with a language provided by the Division.

The “Changes being Effected” supplement (S-005) amends the safety section of the USPI by adding safety information based on the review of the cumulative post-marketing data included in Periodic Safety Update Report (PSUR) 2004.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (package insert (PI) and patient package insert (PPI)).

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions "FPL for approved supplement NDA 21-358/S-004, 005." Approval of these submissions by FDA is not required before the labeling is used.
All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to Division of Reproductive and Urologic Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eufrecina DeGuia, Regulatory Health Project Manager, at (301) 827-4260.

Sincerely,

(See appended electronic signature page)

Daniel Shames, M.D.  
Director  
Division of Reproductive and Urologic Drug Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Daniel A. Shames
3/31/05 03:24:13 PM